FLT3 mutations in childhood acute lymphoblastic leukemia
Open Access
- 1 May 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (9) , 3544-3546
- https://doi.org/10.1182/blood-2003-07-2441
Abstract
Activating mutations of the FLT3 receptor tyrosine kinase are common in acute myelogenous leukemia (AML) but are rare in adult acute lymphoblastic leukemia (ALL). We have recently shown that FLT3 is highly expressed and often mutated in ALLs with rearrangement of the mixed lineage leukemia (MLL) gene on chromosome 11q23. Because hyperdiploid ALL samples also show high-level expression of FLT3, we searched for the presence of FLT3 mutations in leukemic blasts from 71 patients with ALL. The data show that approximately 25% (6 of 25) of hyperdiploid ALL samples possess FLT3 mutations, whereas only 1 of 29 TEL/AML1-rearranged samples harbored mutations (P = .04, Fisher exact test). Three mutations are novel in-frame deletions within a 7-amino acid region of the receptor juxtamembrane domain. Finally, 3 samples from patients whose disease would relapse harbored FLT3 mutations. These data suggest that patients with hyperdiploid or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors. (Blood. 2004;103: 3544-3546)Keywords
This publication has 18 references indexed in Scilit:
- Inhibition of FLT3 in MLLCancer Cell, 2003
- SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinaseBlood, 2002
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)Cancer Cell, 2002
- Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412Cancer Cell, 2002
- Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domainOncogene, 2002
- Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profilingCancer Cell, 2002
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemiaNature Genetics, 2001
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitorsImmunity, 1995